Gyre Therapeutics, Inc. GYRE Gyre — Allocated Share Based Compensation Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre — allocated share based compensation expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre — allocated share based compensation expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — allocated share based compensation expense of $870K in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre — allocated share based compensation expense changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre — allocated share based compensation expense increased by 102.8% year-over-year, from $429K to $870K.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre — allocated share based compensation expense?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre — allocated share based compensation expense has grown at a -23.8% compound annual growth rate (CAGR), from $4.49M to $2.61M.
- What does gyre — allocated share based compensation expense mean?
- This metric represents the portion of total share-based compensation costs allocated to the specific business segment. It reflects the non-cash expense associated with equity-based awards granted to employees and executives working within that segment. Analyzing this helps investors assess the true cost of human capital and potential dilution effects on shareholders.